| dc.contributor.author | Spelman, Timothy | |
| dc.contributor.author | Havrdova, Eva | |
| dc.contributor.author | Horakova, Dana | |
| dc.contributor.author | Trojano, Maria | |
| dc.contributor.author | Lugaresi, Alessandra | |
| dc.contributor.author | Izquierdo, Guillermo | |
| dc.contributor.author | Butzkueven, Helmut | |
| dc.date.accessioned | 2020-06-21T13:11:21Z | |
| dc.date.available | 2020-06-21T13:11:21Z | |
| dc.date.issued | 2018 | |
| dc.identifier.issn | 0028-3878 | |
| dc.identifier.issn | 1526-632X | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/11676 | |
| dc.description | 70th Annual Meeting of the American-Academy-of-Neurology (AAN) -- APR 21-27, 2018 -- Los Angeles, CA | en_US |
| dc.description | Lugaresi, Alessandra/0000-0003-2902-5589; | en_US |
| dc.description | WOS: 000453090800355 | en_US |
| dc.description.abstract | … | en_US |
| dc.description.sponsorship | Amer Acad Neurol | en_US |
| dc.description.sponsorship | Biogen International (Zug, Switzerland) | en_US |
| dc.description.sponsorship | Study Supported by: Biogen International (Zug, Switzerland). | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Lippincott Williams & Wilkins | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis | en_US |
| dc.type | conferenceObject | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 90 | en_US |
| dc.relation.journal | Neurology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
